美国黑人参与癌症临床试验：当前的挑战与解决方案建议。
Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions.
机构信息
Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.
Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX.
出版信息
JCO Oncol Pract. 2021 May;17(5):265-271. doi: 10.1200/OP.21.00001.
Abstract
Low participation of Black Americans in cancer clinical trials is a well-established predicament. Many factors resulted in this current dilemma with racism being the fundamental unit. Here, we discuss some current challenges and proposed solutions to help in increasing the enrollment of Black Americans in cancer clinical trials. We suggest implementing the least acceptable race-specific percentage as a new bar that registrational clinical trials need to pass before cancer drugs approval. Clinical trials will continue to draw the future of cancer therapeutics in which we believe that a prompt improvement of Black Americans participation is warranted.
摘要
美国黑人参与癌症临床试验的比例低是一个既定的困境。许多因素导致了目前的困境，其中种族主义是根本原因。在这里，我们讨论了一些当前的挑战和提出的解决方案，以帮助增加美国黑人参与癌症临床试验的人数。我们建议实施最不可接受的特定种族百分比作为新的标准，注册临床试验需要在批准癌症药物之前通过这个标准。临床试验将继续为癌症治疗的未来绘制蓝图，我们相信有必要迅速提高美国黑人的参与度。
相似文献
1
Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions.
JCO Oncol Pract. 2021 May;17(5):265-271. doi: 10.1200/OP.21.00001.
2
Using Critical Race Theory to Understand Trial Participation Among Black Individuals With Systemic Lupus Erythematosus: A Qualitative Study of Patients and Caregivers.
Arthritis Care Res (Hoboken). 2021 Oct;73(10):1387-1395. doi: 10.1002/acr.24635. Epub 2021 Sep 12.
3
Systemic racism: individuals and interactions, institutions and society.
Cogn Res Princ Implic. 2021 Dec 20;6(1):82. doi: 10.1186/s41235-021-00349-3.
4
Diversity, equity, and inclusion interventions to support admissions have had little benefit to Black students over past 20 years.
J Dent Educ. 2021 Apr;85(4):448-455. doi: 10.1002/jdd.12611. Epub 2021 Apr 7.
5
Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
JAMA Netw Open. 2022 Apr 1;5(4):e228161. doi: 10.1001/jamanetworkopen.2022.8161.
6
Rethinking the issue of reparations for Black Americans.
Bioethics. 2022 Mar;36(3):235-242. doi: 10.1111/bioe.12954. Epub 2021 Sep 13.
7
Perceived stress following race-based discrimination at work is associated with hypertension in African-Americans. The metro Atlanta heart disease study, 1999-2001.
Soc Sci Med. 2004 Feb;58(3):449-61. doi: 10.1016/s0277-9536(03)00211-9.
8
Inclusion of black Americans in oncology clinical trials: the Louisiana State University Medical Center experience.
Am J Clin Oncol. 1999 Feb;22(1):18-21. doi: 10.1097/00000421-199902000-00005.
9
Gain versus loss-framed messaging and colorectal cancer screening among African Americans: A preliminary examination of perceived racism and culturally targeted dual messaging.
Br J Health Psychol. 2016 May;21(2):249-67. doi: 10.1111/bjhp.12160. Epub 2015 Sep 1.
10
Fundamental causes of barriers to participation in Alzheimer's clinical research among African Americans.
Ethn Health. 2021 May;26(4):585-599. doi: 10.1080/13557858.2018.1539222. Epub 2018 Oct 30.
引用本文的文献
1
Innovative Development of Research Engagement Manual: Strategies to Enhance Recruitment and Retention of Black Individuals in Clinical Trials for Substance Use Disorders.
Health Equity. 2025 Aug 22;9(1):387-396. doi: 10.1177/24731242251362181. eCollection 2025.
2
"The more I know, the more you know" Using culturally responsive marketing strategies to develop tools that increase awareness about clinical trials among Black communities.
BMC Public Health. 2025 Sep 1;25(1):3003. doi: 10.1186/s12889-025-24194-x.
3
Bridging the gap: ctDNA, genomics, and equity in breast cancer care.
NPJ Breast Cancer. 2025 Aug 16;11(1):92. doi: 10.1038/s41523-025-00811-1.
4
Callback time preference for prescreening visits among Black residents in the Boston area: findings from two randomized controlled trials.
Trials. 2025 Aug 8;26(1):281. doi: 10.1186/s13063-025-08998-1.
5
A Formative Evaluation of Interventions to Enhance Clinical Trial Diversity Guided by the Socioecological Model.
Cancers (Basel). 2025 Jul 9;17(14):2282. doi: 10.3390/cancers17142282.
6
Engagement in cancer clinical trials among a nationally representative cancer survivor sample: Motivators, barriers and opportunities for improvement.
Tumori. 2025 Aug;111(4):349-359. doi: 10.1177/03008916251347175. Epub 2025 Jun 12.
7
Community perspectives on cancer and cancer research: findings from listening sessions with diverse groups in Philadelphia.
Discov Public Health. 2025;22(1):329. doi: 10.1186/s12982-025-00713-4. Epub 2025 Jun 9.
8
Exceptional Long-term Response to Immunotherapy in an African American Man With -Mutated Metastatic Lung Adenocarcinoma.
J Investig Med High Impact Case Rep. 2025 Jan-Dec;13:23247096251346830. doi: 10.1177/23247096251346830. Epub 2025 May 31.
9
Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study.
JNCI Cancer Spectr. 2025 Mar 3;9(2). doi: 10.1093/jncics/pkaf035.
10
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer.
JAMA Netw Open. 2025 Feb 3;8(2):e2461899. doi: 10.1001/jamanetworkopen.2024.61899.
本文引用的文献
1
Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries.
JAMA Netw Open. 2021 Feb 1;4(2):e210030. doi: 10.1001/jamanetworkopen.2021.0030.
2
Digitizing clinical trials.
NPJ Digit Med. 2020 Jul 31;3:101. doi: 10.1038/s41746-020-0302-y. eCollection 2020.
3
A Time to Dig Deeper and Take Meaningful Action.
J Clin Oncol. 2020 Oct 10;38(29):3361-3362. doi: 10.1200/JCO.20.02158. Epub 2020 Aug 12.
4
Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology.
J Clin Oncol. 2020 Oct 10;38(29):3439-3448. doi: 10.1200/JCO.20.00642. Epub 2020 Aug 12.
5
Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies.
JNCI Cancer Spectr. 2020 Apr 24;4(4):pkaa034. doi: 10.1093/jncics/pkaa034. eCollection 2020 Aug.
6
Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs.
Ann Intern Med. 2020 Aug 18;173(4):320-322. doi: 10.7326/M20-0410. Epub 2020 Jun 23.
7
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
8
Association of Race and Socioeconomic Status With Colorectal Cancer Screening, Colorectal Cancer Risk, and Mortality in Southern US Adults.
JAMA Netw Open. 2019 Dec 2;2(12):e1917995. doi: 10.1001/jamanetworkopen.2019.17995.
9
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.
JAMA Oncol. 2019 Oct 1;5(10):e191870. doi: 10.1001/jamaoncol.2019.1870. Epub 2019 Oct 10.
10
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.
Blood. 2019 Jun 13;133(24):2615-2618. doi: 10.1182/blood.2019000406. Epub 2019 Apr 19.
Zotero 插件